Gene therapy bad news #1: From Pharmalittle newsletter of @statnews.com: "Bluebird Bio announced it would sell itself & its portfolio of gene therapies to the investment firms Carlyle & SK Capital for less than $30 m, in a deal that lets the beleaguered biotech avoid bankruptcy, STAT says. The sale

Comments